📋 Clinical Overview

A live, attenuated, oral vaccine containing a monovalent human rotavirus strain (G1P[8]) for the active immunization of infants against gastroenteritis caused by rotavirus infection. It is a critical component of India's Universal Immunization Programme (UIP) to reduce the significant burden of severe, dehydrating diarrhea in children under five.

💊 Dosage & Administration

Adult: Not indicated for use in adults.
Pediatric: For infants from 6 weeks of age. Two different schedules exist based on the brand (monovalent vs. pentavalent). For the monovalent vaccine (ROTASIIL, ROTAVAC): 3 doses of 0.5 mL (100,000 FFU/dose) each, administered orally at 6, 10, and 14 weeks of age. For the pentavalent vaccine (ROTATEQ): 3 doses of 2 mL each at 6, 10, and 14 weeks. The minimum interval between doses is 4 weeks. The first dose MUST be given between 6 and 15 weeks of age. The entire series MUST be completed by 32 weeks of age.
Renal Adjusment: No dosage adjustment required.
Hepatic Adjusment: No dosage adjustment required.
Instruction: FOR ORAL USE ONLY. DO NOT INJECT. The vaccine is a pale yellow to pink liquid supplied in a squeezable plastic container or a tube. Administer directly into the infant's mouth towards the inner cheek. Do not mix with any other liquid or food. If the infant spits out or regurgitates most of the dose, a single replacement dose may be given at the same visit. The vaccine can be given concurrently with other childhood vaccines (OPV, IPV, DPT, Hepatitis B, Hib, PCV) at different injection sites.

⚠️ Contraindications

History of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any rotavirus vaccine or any component of the vaccine.
History of uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception (e.g., Meckel's diverticulum).
Severe Combined Immunodeficiency Disease (SCID).
Infants older than the maximum age for dose 1 (15 weeks) or the final dose (32 weeks).

🔬 Mechanism of Action

Contains live, attenuated human rotavirus strain. Following oral administration, the virus replicates in the small intestine, mimicking a natural infection but without causing significant disease. This replication stimulates the production of serum neutralizing antibodies (IgG, IgA) and, more importantly, local mucosal IgA antibodies in the gut. These antibodies provide protection against subsequent wild-type rotavirus infection by preventing viral attachment and entry into enterocytes.

🤕 Side Effects

Irritability/Fussiness
Loss of appetite
Mild, transient diarrhea
Mild vomiting
Low-grade fever
Fatigue

🤰 Special Populations

Pregnancy: Not indicated for use in pregnant women.

Lactation: Not indicated for lactating mothers. It is a pediatric vaccine.

Alcohol: Not applicable.

Driving: Not applicable.

🔄 Drug Interactions

Immunosuppressive therapy (e.g., high-dose corticosteroids, chemotherapy, biologics): May diminish the immunologic response to the vaccine, potentially leading to suboptimal protection. Also may increase risk of adverse events due to uncontrolled viral replication. Major
Antiviral agents active against rotavirus (not commonly used): Theoretical interference with vaccine virus replication and immunogenicity. Moderate
Immunoglobulins or blood products: May interfere with the immune response if administered concurrently. It is recommended to defer vaccination for at least 3-6 months after administration of such products. Moderate

ROTARIX (Note: Different strain & titer, included for context)